Inventiva to Participate in Upcoming September Investor Conferences

Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [2][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH, a common and progressive chronic liver disease [2] Upcoming Investor Events - The company will participate in several upcoming investor events, including: - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 PM EDT in New York, NY [1] - 8th Edition of the Lyon Pôle Bourse Forum on September 23, 2025, in Lyon, France [1] - KBC Life Sciences Conference on September 25, 2025, at 5:00 AM EDT in Brussels, Belgium [2] - Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:30 AM EDT, virtually [2] - European MIDCAP Event 2025 from September 30 to October 1, 2025, in Paris, France [2]